Oruka Therapeutics, Inc. (ORKA) Stock Price & Analysis
Oruka Therapeutics, Inc. (ORKA) closed at USD 81.15 on Thursday, October 22, 2026, up 1.54% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 79.92; the Oct 22, 2026 session ranged USD 78.36–82.15 on volume of 589,926 shares. Market capitalization is $5.37B, with a 52-week range of USD 25.23–115.52 (NGM). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ORKA.md
Key facts (ORKA)
- 1 of 80 tracked superinvestors hold ORKA (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Analysts: Buy (mean 1.85 on a 1–5 scale) (13 analysts), mean target USD 155 (range 117–200).
- Total return with dividends: 1Y +199.1% vs S&P 500 +14.9%; 5Y +370.9% vs S&P 500 +80.3%.
- Next earnings: 2026-11-11, EPS estimate USD -0.62, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ORKA)
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0K | $0K | $0K | $0K | — | — |
| Operating income | -$9.8M | -$19.3M | -$10.6M | -$7.3M | -$122M | -$155M |
| Net income | -$9.7M | -$19.3M | -$9.9M | -$5.3M | -$105M | -$133M |
| EPS (diluted) | -$24.84 | -$16.68 | -$8.28 | -$4.44 | — | — |
| Free cash flow | -$7.7M | -$18.8M | -$10.9M | -$5.0M | -$88.4M | -$101M |
| Cash + short-term investments | $49.1M | $53.4M | $42.4M | $37.4M | $337M | — |
| Total debt | $0K | $0K | $0K | $0K | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ORKA)
P/B 4.8x · FCF yield -1.88% · Earnings yield -2.47%
Superinvestors (SEC 13F-HR, Q2 2026) (ORKA)
1 of 80 tracked investors hold ORKA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.41% | $143M | Reduced -43.6% |
Analysts (ORKA)
Consensus Buy (mean 1.85 on a 1–5 scale), 13 analysts; mean target USD 155 (low 117, high 200).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | BTIG | Reiterated | Buy | $151 |
| 2026-09-24 | Wedbush | Reiterated | Outperform | $165 |
| 2026-09-24 | HC Wainwright & Co. | Reiterated | Buy | $120 |
| 2026-09-03 | HC Wainwright & Co. | Reiterated | Buy | $120 |
| 2026-08-11 | Guggenheim | Reiterated | Buy | $200 |
| 2026-08-11 | Wedbush | Reiterated | Outperform | $165 |
| 2026-08-11 | BTIG | Reiterated | Buy | $151 |
| 2026-08-03 | HC Wainwright & Co. | Reiterated | Buy | $120 |
| 2026-07-13 | BTIG | Reiterated | Buy | $151 |
| 2026-07-01 | UBS | Target raised | Buy | $100 → $130 |
Total return (dividends reinvested) (ORKA)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +199.1% | +370.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +200.2% | +36.2% |
| Volatility (annualized) | 66.3% | 62.8% |
| Max drawdown | -36.4% (Aug 2026→Oct 2026) | -74.2% (Oct 2024→Apr 2025) |
ORKA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.62 | $-0.51 | +22.0% | $0 | 9 |
| Next quarter (ends Dec 2026) | $-0.66 | $-0.53 | +24.4% | $0 | 9 |
| Current fiscal year (ends Dec 2026) | $-2.37 | $-2.04 | +16.1% | $0 | 9 |
| Next fiscal year (ends Dec 2027) | $-2.86 | $-2.49 | +14.8% | $0 | 9 |
Key Statistics (as of October 23, 2026 at 09:26 UTC)
| Price | USD 81.15 |
|---|---|
| Change | ▲ 1.54% (up) |
| Previous Close | USD 79.92 |
| Open | USD 79.06 |
| Day Range | USD 78.36 – 82.15 |
| 52-Week Range | USD 25.23 – 115.52 |
| Volume | 589,926 shares |
| Market Cap | $5.37B |
| Exchange | NGM |
Technical Analysis (ORKA)
Nexqual's technical model rates ORKA "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.18 (neutral) |
| vs SMA50 | Below (USD 90.55) |
| MACD | -3.37 (negative) |
Analyst Ratings (ORKA)
Wall Street analysts rate ORKA "Buy" based on 13 analysts, with a mean price target of USD 155 (range USD 117–200), per Nexqual as of October 23, 2026 at 09:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 155 |
| High Target | USD 200 |
| Low Target | USD 117 |
| Buy / Hold / Sell | 13 / 0 / 0 |
Earnings (ORKA)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.62 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.55 vs est -0.5 ▼ miss |
| 2026-03-31 | USD -0.48 vs est -0.54 ▲ beat |
| 2025-12-31 | USD -0.45 vs est -0.62 ▲ beat |
| 2025-09-30 | USD -0.55 vs est -0.52 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financials & Fundamentals (ORKA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -18.23% |
| Debt / Equity | 0 |
| Current Ratio | 38.51 |
| Total Cash | $873.56M |
| Total Debt | $2.55M |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financial Health Score (ORKA)
Nexqual rates Oruka Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:26 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $874M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$88M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -18%, ROA -13.0% |
Ownership (ORKA)
| Insider Ownership | +1.26% |
|---|---|
| Institutional Ownership | +116.93% |
| Shares Outstanding | 66.21M |
| Float | 56.89M |
| Short % of Float | +17.10% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Leadership (ORKA)
Oruka Therapeutics, Inc. is led by Lawrence Otto Klein, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:26 UTC.
| President, CEO & Director | Lawrence Otto Klein |
|---|---|
| Chief Operating Officer | Laura Sandler |
Major Backers & Investors (ORKA)
Notable institutional backers of Oruka Therapeutics, Inc. include FMR, LLC, Venrock Adviser, LLC, Fairmount Funds Management LLC, according to Nexqual as of October 23, 2026 at 09:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 13.68% |
| Venrock Adviser, LLC | 6.27% |
| Fairmount Funds Management LLC | 5.6% |
| Fidelity | 5.43% |
| Capital Group | 5.14% |
| RTW Investments LP | 4.74% |
| Paradigm Biocapital Advisors LP | 3.24% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.54% |
| State Street | 4.04% |
| Vanguard Group | 3.57% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BLTE | Belite Bio, Inc | USD 150.27 | ▼ 1.9% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| TGTX | TG Therapeutics, Inc. | USD 53.16 | ▼ 0.08% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt